Boulder, Colorado – October 24, 2018- Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, will give an oral presentation at the “A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)” meeting being held October 25, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center, 5601 Fishers Lane, Rockville, Maryland.…
Read more
Bolder BioTechnology Announces Presentation at Radiation Injury Treatment Conference
Boulder, Colorado – September 6, 2018 – Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, gave an oral presentation at the “Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency” meeting held August 30, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center,…
Read more
Bolder BioTechnology Announces Publication of Preclinical Studies of BBT-059, a Long-Acting IL-11 Analog, in Mouse Models of the Hematopoietic Acute Radiation Syndrome
Boulder, Colorado – September 5, 2018 – Bolder BioTechnology, Inc. announced today publication of preclinical studies of BBT-059, a long-acting interleukin -11 (IL-11) analog, in mouse models of the hematopoietic acute radiation syndrome. The studies were performed in collaboration with researchers at the Armed Forces Radiobiology Research Institute (AFRRI), the Uniformed Services University of the…
Read more
Bolder BioTechnology Announces Presentation at the 2018 Military Health System Research Symposium
Boulder, Colorado - August 24, 2018 – Bolder BioTechnology is pleased to announce that Dr. Sanchita P. Ghosh of the Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, was selected to give an oral presentation on preclinical studies of BBT-059, Bolder BioTechnology’s long-acting interleukin-11 analog, at the Military Health…
Read more